COVID-19 Vaccines Effective Against Moderate, Severe Disease in Children, Teens
WEDNESDAY, April 19, 2023 (HealthDay News) -- BNT162b2 protects children and adolescents against mild-to-moderate and severe COVID-19, according to a study published online April 7 in Pediatrics.
Nicola P. Klein, M.D., Ph.D., from Kaiser Permanente Northern California in Oakland, and colleagues assessed BNT162b2 vaccine effectiveness against mild-to-moderate and severe COVID-19 in children and adolescents through the omicron BA.4/BA.5 period. The analysis included 9,800 emergency department/urgent care cases with 70,232 controls and 305 hospitalized cases with 2,612 controls.
The researchers found that during the delta variant phase, two-dose vaccine effectiveness against emergency/urgent encounters at 12 to 15 years was initially 93 percent, but waned to 77 percent after ≥150 days. For individuals aged 16 to 17 years, vaccine effectiveness was initially 93 percent but waned to 72 percent after ≥150 days. During the omicron variant phase, vaccine effectiveness for those aged 12 to 15 years was initially 64 percent, waning to 13 percent after ≥150 days, and was 31 percent for those aged 16 to 17 years, waning to 7 percent. A monovalent booster increased vaccine effectiveness to 54 and 46 percent for the two age groups, respectively. For children aged 5 to 11 years, two-dose vaccine effectiveness was initially 49 percent, with waning to 41 percent after 150 days.
"Children and adolescents should receive all recommended COVID-19 vaccinations," the authors write.
Two authors disclosed financial ties to the pharmaceutical industry.
Related Posts
As Clinics Providing Abortions Closed in Iowa, STD Rates Started Rising
MONDAY, Oct. 17, 2022 (HealthDay News) -- Even before the U.S. Supreme Court...
Sleep Disruption Linked to Lower HRQOL in Children
WEDNESDAY, March 15, 2023 (HealthDay News) -- Sleep disruption is associated...
Hospitalizations for Spikes in Blood Pressure Are on the Rise
WEDNESDAY, Nov. 10, 2021 (HealthDay News) -- Despite a nationwide effort to...
Rare Coding Variants May Influence Cognition in Schizophrenia
FRIDAY, Oct. 21, 2022 (HealthDay News) -- Ultrarare constrained variants (URCVs)...